

**MERUS LABS INTERNATIONAL INC.
ANNOUNCES BOARD APPOINTMENT**

Toronto, May 27, 2014 - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today that it has appointed Theresa Firestone to its board of directors. Mrs. Firestone has over 15 years of experience with Pfizer in Canada, Europe, and Asia. She formerly held positions at Pfizer Canada as the General Manager of the Established Products Business Unit, Vice President of Sales, and Vice President, Government & Public Affairs. Mrs. Firestone also gained international experience while on assignment for Pfizer as the Country Manager of Austria and most recently as the Regional President, Emerging Markets Asia located in Shanghai and Hong Kong. Currently, Mrs. Firestone holds the position of Senior Vice President, Healthcare Businesses at Shoppers Drug Mart Canada.

"We are looking forward to Mrs. Firestone's contributions as she brings a wealth of experience across a number of Merus' key operating segments. I view the appointment as the first step in our strategy of augmenting the existing team and bringing on additional pharmaceutical expertise," said Elie Farah, CEO of Merus Labs.

"Mrs. Firestone's impressive background and experience in the Canadian and international pharmaceutical markets will greatly benefit Merus. She brings a complimentary skill set and her insights and expertise will strengthen the Merus board," commented Mr. Michael Cloutier, Chairman of the board of Merus.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Cautionary Statement

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, Merus' ability to complete any financing under its short form prospectus or otherwise, interest rate fluctuations, currency exchange rate

fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus' plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

For further information please contact:

Merus Labs International Inc.

Tel: (416) 593-3725

Or contact our investor relations department at: info@meruslabs.com